tbuckley/cabot-search huggingface dataset:
Attitudes and Practices of Cancer Doctors in the United States regarding Euthanasia and Physician-Assisted Suicide
Journal: Annals of Internal Medicine (2000)

Summaries for Patients3 October 2000Attitudes and Practices of Cancer Doctors in the United States regarding Euthanasia and Physician-Assisted SuicideSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-7-200010030-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?In euthanasia, someone ends the life of a sick person at the sick person's request. Physician-assisted suicide involves a sick person ending his or her own life with the help of a doctor. These practices are very controversial in the United States. Because more than 70% of the patients who request euthanasia or physician-assisted suicide have cancer, the attitudes and behaviors of doctors who treat cancer (oncologists) with respect to these practices are of particular interest.Why did the researchers do this particular study?To understand better the ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Attitudes and Practices of U.S. Oncologists regarding Euthanasia and Physician-Assisted Suicide.” It is in the 3 October 2000 issue of Annals of Internal Medicine (volume 133, pages 527-532). The authors are EJ Emanuel, D Fairclough, BC Clarridge, D Blum, E Bruera, WC Penley, LE Schnipper, and RJ Mayer.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAttitudes and Practices of U.S. Oncologists regarding Euthanasia and Physician-Assisted Suicide Ezekiel J. Emanuel , Diane Fairclough , Brian C. Clarridge , Diane Blum , Eduardo Bruera , W. Charles Penley , Lowell E. Schnipper , and Robert J. Mayer Metrics 3 October 2000Volume 133, Issue 7Page: I-39KeywordsBehaviorCancer treatmentEuthanasiaPatientsProstate cancerSuicide ePublished: 3 October 2000 Issue Published: 3 October 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Correction
Journal: BMJ (1948)

Hay-fever due to Ragweed Pollen Q.-An Anmerican suffering from a severe form of hay-fever chiefly duie to ragweed pollen intends to visit Europe (Britishl Isles, France, Switzerlan(d) tkis summer.He asks whether ra,- weed grows in these countries, and, if so, whzich are its months of flowering?A.-The ragweeds (Ambrosia spp.) are native to North America and exist in Europe only as introductions.Five species have been noted at various times and places in Great Britain as alien or adventitious plants, usually in the neighbour- hood of ports.One-namely, Short Ragweed (A. artemisiae- folia)-is known to have been established at one time at St. Annes, Lancashire.The same species is reported as having occurred in France, mainly near certain ports, and also at a number of distinct localities in Switzerland.Ragweed pollen is easy to recognize, but only one grain has ever been seen on the thousands of slides the writer has exposed in various places in Great Britain since 1941.Unless an American visitor happened by mischance to walk into a colony of rag- weed such as may perhaps exist here and there it is extremely unlikely that he would be exposed to this type of pollen in Europe.The months of flowering in Europe, as in U.S. A., are
Stem cells: science, policy, and ethics
Authors: Gerald D. Fischbach, Ruth L. Fischbach
Journal: Journal of Clinical Investigation (2004)

The definition of "totipotent" was incorrectly identified as "Cell committed to a specific lineage that is capable of giving rise to all types of differentiated cells and tissues, including extraembryonic tissues."The correct definition is "Cell not committed to a specific lineage that is capable of giving rise to all types of differentiated cells and tissues, including extraembryonic tissues."
Railroad Rates.
Authors: Albert Pick
Journal: JAMA (1897)

the requirements of school with comfort, we search for an error of refraction, which if found, is corrected, if need be, with glasses.Again, the fact that very many children and adults have a greater or less amount of some one or more of these errors, and when rendered uncomfortable by it the knowledge that comfort and its privileges can be enjoyed by its correction with a pair of specially arranged glasses, it need not be won- dered that many will wear them.'
Diagnosing Delirium
Authors: Finn M. Radtke, Jean-David Gaudreau, Claudia Spies
Journal: JAMA (2010)

To the Editor: Dr Wong and colleagues1 provided a systematic review that included discussion of easy-to-use bedside instruments to detect delirium; such tools are paramount in early diagnosis and treatment. However, there are 2 important additional aspects that we would like to address.
Interference Halts 'Ping Pong' Staph
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FACTORS IN THE REGENERATION OF BLOOD
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib
Authors: D. R. Ferry, M. Anderson, K. Beddows, P. Mayer, L. Price, J. Jankowski
Journal: Journal of Clinical Oncology (2004)

4021 Background: At presentation, most cases of adenocarcinoma of the oesophagus (ACO) are inoperable and, although chemotherapy with cisplatin/5-fluorouracil can prolong survival, patients eventually die as a result of refractory disease. Expression of epidermal growth factor receptor (EGFR) is a negative prognostic factor. EGFR is almost universally expressed in ACO; however, it is inhibited by the tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839). Methods: A Phase II clinical trial was conducted in patients with ACO who had received 1 previous chemotherapy regimen for advanced disease, relapsed after surgery and neoadjuvant chemotherapy, declined chemotherapy or been too ill for chemotherapy. A total of 27 patients were to be recruited using a 2-stage design. Biopsies were taken before and 28 days after treatment with gefitinib 500 mg/day. Tumour response was assessed using RECIST. Results: There were 23 men and 4 women with a median (range) age of 60 (46–82) years. Twenty patients had previous chemotherapy and 7 had no prior chemotherapy. All 27 patients were evaluable for toxicity; 26 were evaluable for tumour response. Toxicity was mild: rash (grade 2/3) occurred in 7 patients and diarrhoea (≥grade 2) in 4 (2 were grade 3/4). Biopsies taken pre- and post-treatment were evaluated in 7 patients; 5 showed a decrease in Ki67 expression. Genomic analysis is ongoing. Three patients (12%) had a partial response (PR) (duration: 120, 188 and 313+ days), 12 had stable disease (SD) and 11 had disease progression. Of those patients with a PR, 1 had prior neoadjuvant chemotherapy, 1 had received chemotherapy for advanced disease and 1 had received gefitinib as primary therapy. Conclusions: Gefitinib 500 mg/day is an active treatment for ACO with a disease control rate (PR or SD) of 58% (15/26 patients). Biopsies indicate that gefitinib inhibits biological pathways. Further trials of gefitinib would seem warranted, especially as patient response appears to be highly durable, and current chemotherapy second-line options have infrequent activity and are often toxic. 'Iressa' is a trademark of the AstraZeneca group of companies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca Pharmaceuticals AstraZeneca AstraZeneca
THE MOST EXPENSIVE OPERATION
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary
Authors: Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy
Journal: Journal of the American College of Cardiology (2011)
Childhood asthma.
Authors: N M Clark, R W Brown, E Parker, T G Robins, D G Remick, M A Philbert, G J Keeler, B A Israel
Journal: Environmental Health Perspectives (1999)

Asthma prevalence in children has increased 58% since 1980. Mortality has increased by 78%. The burden of the disease is most acute in urban areas and racial/ethnic minority populations. Hospitalization and morbidity rates for nonwhites are more than twice those for whites. Asthma is characterized by recurrent wheezing, breathlessness, chest tightness, and coughing. Research in the past decade has revealed the importance of inflammation of the airways in asthma and clinical treatment to reduce chronic inflammation. Asthma is associated with production of IgE to common environmental allergens including house dust mite, animal dander, cockroach, fungal spores, and pollens. Some interventions to reduce symptoms through control of dust mite and animal dander have had positive results. Control of symptoms through interventions to reduce exposures to cockroach antigen has not been reported. Studies illustrating causal effects between outdoor air pollution and asthma prevalence are scant. Increases in asthma prevalence have occurred at the same time as general improvements in air quality. However, air quality appears to exacerbate symptoms in the child who already has the disease. Decreased pulmonary function has been associated with exposure to particulates and bronchial hyperresponsiveness to smoke, SO(2) and NO(2). Symptoms have been correlated with increased levels of respirable particulates, ozone, and SO(2). Interventions that reduce the negative outcomes in asthma associated with outdoor environmental factors have not been reported. Control of asthma in children will entail the collaborative efforts of patients, family, clinical professionals, and school personnel, as well as community-wide environmental control measures and conducive national and local policies based on sound research.
DOMESTIC CORRESPONDENCE.
Authors: None Iowa.
Journal: JAMA (1892)

tiful valleys, torrents and streams, its majestic scenery, its thriving towns and cities, rendered rich by local industries, its mines and its forests, its palaces, cathedrals, schools, and museums-the whole thing brought out in relief by the vestiges of its immortal past, a double civilization in strik¬ ing contrast !"Should we leave unmentioned its delightful climate, its blue sky, its wonderful fruits and beautiful flowers?"But above all stand the noted courtesy, the exquisite refinement of its inhabitants, who have made us at home
A Stool DNA Test (Cologuard) for Colorectal Cancer Screening
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cochrane Collaboration
Authors: F Godlee
Journal: BMJ (1994)

Health starts the bidding with a recommended exposure limit for nitrous oxide of 25 ppm as a time weighted average during the period for which anaesthetics are given, while the standard of the American conference of governmental industrial hygienists is 50 ppm as an eight hour time weighted average.The current proposal of 100 ppm being considered at present by the British Health and Safety Commission6 will, if agreed, be implemented next January.Those wishing to bid higher will argue that the resources required to achieve lower concentrations are not appropriate to the degree of risk.The lowest bid will, of course, require the highest resources.The proposal from the National Institute of Occupational Health and Safety is particularly courageous in this respect, and many would consider the investment required to achieve that standard to be a major burden relative to the risk, particularly in dentistry, paediatric surgery, and delivery rooms in maternity hospitals, where control is more difficult to achieve.The alert goes further in recommending that when nitrous oxide concentrations exceed 25 ppm workers should ensure that they are sup- plied with respirators similar to those used in asbestos stripping procedures.At this point the practical difficulties of this proposal in a health care environment escalate beyond belief.
OCULAR ANAPHYLAXIS
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
On the Contributions of Hugh Owen Thomas of Liverpool, Sir Robert Jones of Liverpool and London, John Ridlon, M.D., of New York and Chicago to Modern Orthopedic Surgery
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Accuracy of precordial percussion and palpation
Authors: D. H. Spodick
Journal: JAMA (1994)

<h3>In Reply.</h3> —We thank Dr Gerber and colleagues for their endorsement of our recommendation for more randomized controlled trials of behavior change intervention for HIV and sexually transmitted disease prevention. We also commend the references they cite as excellent overviews of behavioral interventions to prevent HIV. Higgins et al<sup>1</sup>document the paucity of randomized trials. Kelly,<sup>2</sup>a pioneer in HIV-related community intervention trials, writes: "After more than 12 years of the HIV epidemic—an epidemic that can only be controlled by interventions to promote risk behavior change— the lack of research evaluating outcomes of interventions to prevent HIV infection is very troubling." Our call for more randomized trials of behavioral interventions has been misinterpreted by some as a statement that behavioral interventions do not work. We believe that some behavioral interventions, like some drug therapy interventions, are effective in some instances. Randomized controlled trials help determine which interventions are
In This Issue
Journal: Circulation Research (2010)

Macrophage ABCA1 and SR-BI in Atherogenesis (p e20)Zhao et al report that two fatshifting factors work synergistically to keep macrophages healthy and atherosclerosis at bay.Despite their voracious appetite, macrophages are unable to fully digest the lipids they ingest.Instead, they rely on factors, such as ABCA1, to export excess cholesterol out of the cell.Lipid accumulation inside macrophages can result in their transformation into foam cells that give rise to atherosclerotic plaques.Indeed, loss of ABCA1 from macrophages has been reported to increase atherosclerotic lesion formation.SR-B1 is another macrophage cholesterol exporter, but it also promotes cholesterol uptake by the liver.Deletion of SR-B1 from macrophages both enhances progression of advanced atherosclerotic lesions and inhibits development of early lesions.Zhao et al wondered what would happen if SR-B1 and ABCA1 were deleted together.They discovered that in atheroscleroticprone mice, macrophage-specific deletion of SR-B1 alone caused a large increase in serum cholesterol, whereas deletion of ABCA1 caused a decrease.When both factors were deleted together, serum cholesterol levels were decreased even further.Combined deletion also increased the formation of foam cells and of atherosclerotic lesions.Therefore, a two-pronged approach at increasing these factors' activities might be an avenue for antiatherosclerotic therapies.
BOOK REVIEWS
Authors: H. E. KAISER
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article BOOK REVIEWS Get access Familial Adenomatous Polyposis . Lemuel Herrera , ed. New York : Alan R. Liss, Inc. , 1989 , 430 pp. $129.50. HANS E. KAISER HANS E. KAISER Department of Pathology, University of Maryland, School of Medicine 10 S. Pine St. Baltimore, MD 21201 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 17, 5 September 1990, Page 1430, https://doi.org/10.1093/jnci/82.17.1430 Published: 05 September 1990